# Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors

> **NCT00804310** · PHASE1 · TERMINATED · sponsor: **University of California, Davis** · enrollment: 5 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** ixabepilone
- **DRUG:** lapatinib ditosylate

## Key facts

- **NCT ID:** NCT00804310
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2012-03-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00804310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00804310, "Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00804310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*